Clinical Guidelines

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

Share

  • 1

    ES-SCLC has a poor prognosis with a 5-10% 5-year survival rate.

  • 2

    First-line treatment includes carboplatin and etoposide + immunotherapy.

  • 3

    Immunotherapy agents durvalumab and atezolizumab improve survival rates.

  • 4

    Managing oncologic emergencies like SIADH is critical.

  • 5

    Tarlatamab is a preferred second-line therapy based on improved survival.

  • 6

    Importance of supportive care and monitoring adverse effects is emphasized.

  • 7

    New FDA approvals enhance options for maintenance therapy.

Original Source(s)

Latest Clinical Evidence in Extensive-Stage Small Cell Lung Cancer Treatment

  • by Stephanie McDonald, MSN, FNP-BC, AOCNP, Elizabeth Castronovo, MSN, AGNP-BC

  • February 27, 2026

  • 8 min

Related Content

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min
Case Study: ICU-Based Chemotherapy for High-Risk Cardiac DLBCL Patient

A 34-year-old woman with newly diagnosed mediastinal diffuse large B-cell lymphoma developed alarming cardiac symptoms during her initial hospitalization.

  • by

  • January 31, 2026

  • 4 min
Uncovering and Addressing Implicit Bias in Oncology

  • April 24, 2023

  • 12 min